TScan Therapeutics taps Jason A. Amello, financial leader extraordinaire.

TScan Therapeutics, a clinical-stage biopharmaceutical company, has appointed Jason A. Amello as its new Chief Financial Officer. Amello previously served as the CFO of Candel Therapeutics and has held similar positions at other pharmaceutical companies. He replaces Brian Silver, who left TScan in July. The hiring of Amello will support TScan as it continues to advance its pipeline of T-cell receptor (TCR) therapeutics.